Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVTX Travere Therapeutics, Inc.

未开盘 03-02 16:00:00 EST

29.53

-0.26

-0.87%

盘后29.53

+0.000.00%

19:53 EST

最高29.98	最低28.99	成交量191.54万
今开29.28	昨收29.79	日振幅3.32%
总市值27.24亿	流通市值26.94亿	总股本9,224万
成交额5,657万	换手率2.10%	流通股本9,122万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVTX","market":"US","secType":"STK","nameCN":"Travere Therapeutics, Inc.","latestPrice":29.53,"timestamp":1772485200000,"preClose":29.79,"halted":0,"volume":1915394,"hourTrading":{"tag":"盘后","latestPrice":29.53,"preClose":29.53,"latestTime":"19:53 EST","volume":216457,"amount":6391970.4877,"timestamp":1772499216169,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.008727760993621955,"floatShares":91220000,"shares":92241550,"eps":-0.286352,"marketStatus":"未开盘","change":-0.26,"latestTime":"03-02 16:00:00 EST","open":29.28,"high":29.98,"low":28.99,"amount":56568403.622640006,"amplitude":0.033233,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.286352,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772528400000},"marketStatusCode":0,"adr":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":29.79,"preHourTrading":{"tag":"盘前","latestPrice":29.79,"preClose":29.79,"latestTime":"09:19 EST","volume":32608,"amount":971118.999744,"timestamp":1772461171190,"change":0,"changeRate":0,"amplitude":0.031279},"postHourTrading":{"tag":"盘后","latestPrice":29.53,"preClose":29.53,"latestTime":"19:53 EST","volume":216457,"amount":6391970.4877,"timestamp":1772499216169,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.405161,"impliedVol":1.4028,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/TVTX/wiki","defaultTab":"wiki","newsList":[{"id":"1153311018","title":"Travere Therapeutics公布关于Filspari在FSGS的第三阶段Duplex研究的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153311018","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153311018?lang=zh_cn&edition=full","pubTime":"2025-11-07 00:01","pubTimestamp":1762444873,"startTime":"0","endTime":"0","summary":"Travere Therapeutics公布关于Filspari在FSGS的第三阶段Duplex研究的最新数据，数据将在2025年美国肾脏病学会（ASN）肾脏周期间发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"gpt_icon":0},{"id":"2567190639","title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","url":"https://stock-news.laohu8.com/highlight/detail?id=2567190639","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567190639?lang=zh_cn&edition=full","pubTime":"2025-09-13 06:38","pubTimestamp":1757716705,"startTime":"0","endTime":"0","summary":"研发新冠疫苗的BioNTech盘中跌超10%、莫德纳跌超7%、Novavax跌超4%。投资者担心，如果特朗普政府进一步收紧疫苗接种政策，可能对疫苗制造商的业务造成重大冲击，特别是对莫德纳这类高度依赖新冠疫苗收入的公司。更新中","market":"us","thumbnail":"https://static.tigerbbs.com/632b4e916ff966270173f4303843021f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/632b4e916ff966270173f4303843021f"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3755508","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ae8bc75ba4d1918dcafc0476d86c6d53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3755508","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["STRO","TVTX","ABUS","BMY","NVS","ARCT","AZN","SRPT","PFE","MRNA","BNTX","KALV","PGEN","TARS","NVAX","TRVI","MRK","PSNL","BK4009"],"gpt_icon":1},{"id":"1171090232","title":"FDA批准跳过咨询委员会审查，Travere Therapeutics股价盘前大涨17.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171090232","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171090232?lang=zh_cn&edition=full","pubTime":"2025-09-10 20:26","pubTimestamp":1757507176,"startTime":"0","endTime":"0","summary":"Travere Therapeutics股价在盘前交易中大幅上涨17.8%，此前美国食品药品监督管理局(FDA)批准该公司的肾脏疾病治疗药物可以跳过咨询委员会的审查程序。这一决定为该公司的药物审批流程提供了便利，投资者对此消息反应积极，推动股价显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139"],"gpt_icon":0},{"id":"1140041580","title":"Travere Therapeutics就Filspari®（Sparsentan）治疗FSGS的FDA咨询委员会会议提供最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1140041580","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140041580?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:03","pubTimestamp":1757502183,"startTime":"0","endTime":"0","summary":"Travere Therapeutics公司发布了关于其药物Filspari®（Sparsentan）用于治疗FSGS的FDA咨询委员会会议的最新情况说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"gpt_icon":0},{"id":"2514868388","title":"小摩：维持Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级, 目标价由42.00美元调整至44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514868388","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514868388?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:58","pubTimestamp":1740589098,"startTime":"0","endTime":"0","summary":"小摩：维持Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级, 目标价由42.00美元调整至44.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27005848413817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"1190867740","title":"异动解读 | Travere Therapeutics股价盘中大涨5.91% 投资者看好罕见肾病新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1190867740","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190867740?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:31","pubTimestamp":1740583910,"startTime":"0","endTime":"0","summary":"生物制药公司Travere Therapeutics股价当日盘中大涨5.91%,投资者对公司研发的罕见肾病新药sparsentan的前景看好。Travere Therapeutics专注于为患有罕见肾脏、肝脏和代谢疾病的人研发新药。其在研新药sparsentan是治疗局灶节段性肾小球硬化症和IgA肾病的后期候选药物,如果顺利获批上市,将为公司带来重大利好。虽然公司目前净利润为负,但营收和毛利较高,处于盈利前投入期正常状态。投资者看好sparsentan获批并推动公司业绩大幅增长的预期,推动了当日股价大涨超5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Travere Therapeutics股价盘中大涨5.91% 投资者看好罕见肾病新药前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"gpt_icon":0},{"id":"2514854832","title":"Travere Therapeutics, Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514854832?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:24","pubTimestamp":1740583442,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时24分，Travere Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Enveric Biosciences, Inc.、Athira Pharma, Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5090.48%、184.17%、177.50%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Organovo Holdings, Inc.，振幅分别为161.02%、39.47%、33.94%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226232403a2550337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226232403a2550337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX","BK4139"],"gpt_icon":0},{"id":"2514677689","title":"花旗：维持Travere Therapeutics(TVTX.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514677689","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514677689?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:25","pubTimestamp":1740414342,"startTime":"0","endTime":"0","summary":"花旗：维持Travere Therapeutics(TVTX.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至35.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25002548356350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TVTX","LENZ"],"gpt_icon":0},{"id":"2513877337","title":"Travere Therapeutics, Inc.盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513877337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513877337?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:58","pubTimestamp":1740409101,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时58分，Travere Therapeutics, Inc.股票出现波动，股价大幅下挫5.09%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为148.73%、63.61%、25.10%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225821abdb1489&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225821abdb1489&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX","BK4139"],"gpt_icon":0},{"id":"2513375644","title":"Travere Therapeutics, Inc.2024财年实现净利润-3.21亿美元，同比增加14.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513375644","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513375644?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326471,"startTime":"0","endTime":"0","summary":"2月24日，Travere Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.21亿美元，同比增加14.63%；其中营业收入为2.33亿美元，同比增加60.69%，每股基本收益为-4.08美元。机构评级：截至2025年2月24日，当前有14家机构对Travere Therapeutics, Inc.目标价做出预测，其中目标均价为34.21美元，其中最低目标价为22.00美元，最高目标价为47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141a250ce13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141a250ce13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"2513136242","title":"坎托菲茨杰拉德公司：重申Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513136242","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513136242?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:34","pubTimestamp":1740159250,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22013448321042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TVTX","LENZ"],"gpt_icon":0},{"id":"2513778299","title":"Travere Therapeutics, Inc.盘中异动 股价大跌9.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778299?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Travere Therapeutics, Inc.股票出现波动，股价快速跳水9.92%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Acelyrin, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.10%、60.32%、17.96%，振幅较大的相关个股有Osr Holdings, Inc.、Gain Therapeutics, Inc.、Windtree Therapeutics, Inc.，振幅分别为11.30%、10.21%、7.29%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223115abd7af4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223115abd7af4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVTX","LENZ","BK4139"],"gpt_icon":0},{"id":"1165114656","title":"Travere Therapeutics 第四季度调整后每股亏损 $-0.47 超预期，销售额 $7479万 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165114656","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165114656?lang=zh_cn&edition=full","pubTime":"2025-02-21 05:04","pubTimestamp":1740085466,"startTime":"0","endTime":"0","summary":"根据NASDAQ TVTX报道，Travere Therapeutics 公司报告了季度每股亏损 $-0.47，这一数据比分析师普遍预测的 $-0.56 高出 16.07%。相比去年同期每股亏损 $-0.94，有50%的上涨。相比去年同期的 $4506万，销售额增长了 65.98%。以上内容来自Benzinga Earnings专栏，原文如下：Travere $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 16.07 percent. This is a 50 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $74.79 million which beat the analyst consensus estimate of $73.34 ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"2510370128","title":"Evercore ISI Group：维持Travere Therapeutics(TVTX.US)评级，由优于大市调整至优于大市评级, 目标价由33.00美元调整至45.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510370128","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510370128?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370757,"startTime":"0","endTime":"0","summary":"Evercore ISI Group：维持Travere Therapeutics(TVTX.US)评级，由优于大市调整至优于大市评级, 目标价由33.00美元调整至45.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12223248121880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX","EVR"],"gpt_icon":0},{"id":"2510338744","title":"Travere Therapeutics, Inc.盘中异动 大幅上涨13.93%报24.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510338744?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:31","pubTimestamp":1739284264,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时31分，Travere Therapeutics, Inc.股票出现异动，股价大幅拉升13.93%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.92%。其相关个股中，Dominari Holdings Inc.、In8Bio, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.较为活跃，换手率分别为1857.07%、501.54%、169.16%，振幅较大的相关个股有In8Bio, Inc.、Dominari Holdings Inc.、Abpro Holdings, Inc，振幅分别为11.26%、8.44%、6.12%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223104a241fac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223104a241fac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TVTX","LENZ"],"gpt_icon":0},{"id":"2510865602","title":"Travere Therapeutics, Inc.盘中异动 早盘股价大跌5.23%报20.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510865602?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:39","pubTimestamp":1739198378,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时39分，Travere Therapeutics, Inc.股票出现异动，股价急速下跌5.23%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为1911.49%、1022.03%、683.97%，振幅较大的相关个股有Soligenix, Inc.、Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.，振幅分别为103.16%、50.12%、34.46%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223938abc9a743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223938abc9a743&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2505259240","title":"Travere Therapeutics, Inc.盘中异动 下午盘急速上涨5.04%报20.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505259240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505259240?lang=zh_cn&edition=full","pubTime":"2025-01-24 04:15","pubTimestamp":1737663342,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日04时15分，Travere Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.44%。其相关个股中，Dogwood Therapeutics, Inc.、Transcode Therapeutics, Inc.、Nutriband Inc C/Wts 涨幅较大，Dogwood Therapeutics, Inc.、Hepion Pharmaceuticals, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为7340.77%、7203.66%、1106.39%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Transcode Therapeutics, Inc.、Nutriband Inc C/Wts ，振幅分别为948.57%、261.32%、172.73%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124041542960e827d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124041542960e827d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TVTX"],"gpt_icon":0},{"id":"2505271090","title":"Travere Therapeutics, Inc.盘中异动 股价大涨5.06%报19.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505271090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505271090?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:49","pubTimestamp":1737470951,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时49分，Travere Therapeutics, Inc.股票出现波动，股价快速拉升5.06%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.20%。其相关个股中，Channel Therapeutics Corporation、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Dogwood Therapeutics, Inc.涨幅较大，Dogwood Therapeutics, Inc.、Dermata Therapeutics, Inc.、Channel Therapeutics Corporation较为活跃，换手率分别为619.02%、167.17%、80.96%，振幅较大的相关个股有Channel Therapeutics Corporation、Dogwood Therapeutics, Inc.、Atara Biotherapeutics, Inc.，振幅分别为85.26%、38.48%、17.50%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121224912a22a5b49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121224912a22a5b49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TVTX"],"gpt_icon":0},{"id":"2488094156","title":"Travere Therapeutics, Inc.盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488094156","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488094156?lang=zh_cn&edition=full","pubTime":"2024-12-03 01:12","pubTimestamp":1733159522,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日01时12分，Travere Therapeutics, Inc.股票出现异动，股价快速拉升5.10%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Senti Biosciences, Inc.、Purple Biotech Ltd、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Senti Biosciences, Inc.、Purple Biotech Ltd、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为2209.95%、2176.22%、590.18%，振幅较大的相关个股有Senti Biosciences, Inc.、Purple Biotech Ltd、Quoin Pharmaceuticals Ltd，振幅分别为481.02%、289.12%、131.67%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203011202971b33ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203011202971b33ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TVTX"],"gpt_icon":0},{"id":"2486884775","title":"Travere Therapeutics, Inc.盘中异动 快速上涨5.01%报19.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486884775?lang=zh_cn&edition=full","pubTime":"2024-11-27 02:07","pubTimestamp":1732644475,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日02时07分，Travere Therapeutics, Inc.股票出现异动，股价快速上涨5.01%。截至发稿，该股报19.09美元/股，成交量43.076万股，换手率0.49%，振幅4.73%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112702075598e44bc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112702075598e44bc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://travere.com","stockEarnings":[{"period":"1week","weight":-0.039},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.1312},{"period":"6month","weight":0.5059},{"period":"1year","weight":0.3799},{"period":"ytd","weight":-0.2272}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Travere Therapeutics, Inc.于2008年2月8日合并为Desert Gatewayinc公司，注册于俄克拉何马州。 Retrophin是一家处于发展阶段的生物制药公司，致力于严重疾病、灾难性疾病以及罕见疾病的治疗疗法的开发、收购和商业化。Retrophin在美国，正致力于开发 SyntocinonTM Nasal Spray，以帮助产后乳汁分泌, 并且可以用于治疗精神分裂症和自闭症。Syntocinon Nasal Spray目前由Novartis 和 Sigma-Tau 负责在欧洲以及其他国家销售，帮助孕妇产后乳汁分泌。此外, Retrophin正在开发RE-034, 一种合成激素类似物, 由包含在ACTH中39个氨基酸中的24个氨基酸组成，用以治疗婴儿痉挛症和肾病综合症。Retrophin 同时也致力于研发re - 024, 一种新型小分子, 用于泛酸盐神经退行性病变的潜在治疗。同时,该公司正在开发sparsentan, 原名为re - 021, 双重作用的血管紧缩素受体和内皮素受体, 用于治疗局灶节段性肾小球硬化症。Retrophin在临床开发方面也有几个额外的程序,包括re - 001，用于杜氏肌萎缩症的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.008601},{"month":2,"riseRate":0.615385,"avgChangeRate":0.073426},{"month":3,"riseRate":0.384615,"avgChangeRate":0.013615},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.045444},{"month":5,"riseRate":0.5,"avgChangeRate":0.011933},{"month":6,"riseRate":0.583333,"avgChangeRate":0.032284},{"month":7,"riseRate":0.5,"avgChangeRate":0.010273},{"month":8,"riseRate":0.5,"avgChangeRate":0.058304},{"month":9,"riseRate":0.416667,"avgChangeRate":0.007125},{"month":10,"riseRate":0.5,"avgChangeRate":0.033214},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03497},{"month":12,"riseRate":0.583333,"avgChangeRate":0.053144}],"exchange":"NASDAQ","name":"Travere Therapeutics, Inc.","nameEN":"Travere Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Travere Therapeutics, Inc.(TVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Travere Therapeutics, Inc.,TVTX,Travere Therapeutics, Inc.股票,Travere Therapeutics, Inc.股票老虎,Travere Therapeutics, Inc.股票老虎国际,Travere Therapeutics, Inc.行情,Travere Therapeutics, Inc.股票行情,Travere Therapeutics, Inc.股价,Travere Therapeutics, Inc.股市,Travere Therapeutics, Inc.股票价格,Travere Therapeutics, Inc.股票交易,Travere Therapeutics, Inc.股票购买,Travere Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Travere Therapeutics, Inc.(TVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}